Stable Quality Omeprazole Enteric-Coated Tablets 0.1g*36 Tablets for Sale

Name: Stable Quality Omeprazole Enteric-Coated Tablets 0.1g*36 Tablets for Sale
Brand: Shandong New Time Pharmaceutical Co., Ltd.
SKU: 1917284612

Shandong, ChinaShandong New Time Pharmaceutical Co., Ltd.

US$5.50-6.00

100 box

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

For oral administration

Model NO.

Omeprazole Enteric-coated Tablets

Suitable for

Elderly, Children, Adult

State

Solid

Shape

Tablet

Type

Biological Products

Pharmaceutical Technology

Chemical Synthesis

Drug Reg./Approval No.

H20044871

Drug Ad Approval No.

Undetermined

Color

White or Almost White Without Coating

Free Simple

Not Available

Term of Validity

24 Months

Taste

Bitter

Packing

0.1g*36 Tablets Per Box

Transport Package

Carton

Specification

0.1g

Trademark

New Time

Origin

China

HS Code

3004909090

Production Capacity

1000000 Boxes/Year

Company profile

Shandong New Time Pharmaceutical Co., Ltd.

Shandong, China

CertifiedBusiness Type: Manufacturer/Factory CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2003-06-01 CertifiedNearest Port: Qingdao PortAverage Response Time: >24h CertifiedTerms of Payment: LC, T/T, D/P

AI-Powered supplier vetting

SummaryShandong New Time Pharmaceutical Co., Ltd. is a China-based manufacturer established in 2001, with 4,330 employees and operations in Shandong. It produces pharmaceutical and chemical products, including potassium clavulanate formulations, amoxicillin and clavulanate potassium, sevoflurane, isoflurane, and orlistat. The supplier reports ISO 14001:2015 and ISO 45001:2016 certifications, more than 1,265 years of combined R&D engineer experience, 50 quality-control staff, and more than 10 production lines. Its stated export coverage includes major global regions, while transaction records evidence customers in Mexico and Vietnam for orlistat and potassium clavulanate-related products. The evidence supports substantial manufacturing scale, international market reach, and R&D resources, but does not establish after-sales processes, customization services, financial credibility, or broad customer performance outcomes.

Supplier typeThe supplier is explicitly identified as a manufacturer and operates in the pharmaceutical and chemical sectors. Its stated products include active pharmaceutical ingredients and pharmaceutical formulations, which directly supports classification as a pharmaceutical manufacturer.

CertificationsThe supplier reports ISO 14001:2015 and ISO 45001:2016 certificates. These explicitly evidence certified environmental-management and occupational-health-and-safety management systems, although no product-specific or pharmaceutical GMP certification is provided in the supplied information.

R&D capabilityThe supplier states that it maintains an independent innovation system, has a technology center ranked at the forefront of the domestic pharmaceutical industry, and has technology partnerships with more than 100 institutes and universities. It also reports 1,265 years of total R&D engineer experience, providing explicit evidence of substantial R&D resources and innovation activity.

Production capacityThe supplier reports 4,330 employees, more than 10 production lines, 50 quality-control staff, and a broad pharmaceutical product portfolio. Product records document production of potassium clavulanate with microcrystalline cellulose in February 2025, while the reported export coverage spans multiple global regions; the manufacturing plant area is recorded as ".0m²" and therefore does not provide a usable facility-size measure.

Client casesTrade records identify a Mexican buyer for orlistat and orlistat samples, and a Vietnamese buyer for potassium clavulanate with microcrystalline cellulose. These records provide concrete evidence of transactions with customers in Mexico and Vietnam, but the limited number of disclosed transactions does not demonstrate broad customer references or long-term performance.